vorinostat has been researched along with Leukemia, Megakaryocytic in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galimberti, S | 2 |
| Canestraro, M | 2 |
| Maffei, R | 2 |
| Marasca, R | 2 |
| Guerrini, F | 2 |
| Piaggi, S | 1 |
| Ciabatti, E | 1 |
| Petrini, M | 2 |
| Khan, R | 1 |
| Buda, G | 1 |
| Orciuolo, E | 1 |
| Fazzi, R | 1 |
2 other studies available for vorinostat and Leukemia, Megakaryocytic
| Article | Year |
|---|---|
Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Electrophoretic | 2009 |
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Screening | 2008 |